Dismiss Alert

Flu Season Hospital Visitor Limitations

Temporary limitations are in place for hospital visitors. Visitors must be 18 years or older and not exhibit any flu symptoms.

Research plays an important role in cardiology advancement. Through research, we can make more progress to benefit young heart patients. 

At Loma Linda University Children’s Health, our pediatric cardiology teams are active participants in the following research and clinical trials. 

Cardiac Catheterization Research

Our cardiac catheterization team contributes to national registries that promote quality improvements and develop outcome assessment methods for pediatric catheterization. They also participate in FDA clinical trials for devices and transcatheter therapies performed in the United States. 

National Registries 

  • National Cardiovascular Data Registry’s IMPACT Registry™ (Improving Pediatric and Adult Congenital Treatment)
  • Congenital Cardiovascular Interventional Study Consortium (CCISC) 

Clinical Trials 

  • Use of covered Cheatham Platinum Stents for treatment of vascular wall injury involving surgical placed conduits between the right ventricle and the pulmonary arteries (PARCS)
    • Primary Investigator: Brent Gordon, MD 
  • Post-market trial for NitOcclud PDA closure device
    • Primary Investigator: Brent Gordon, MD 
  • Post-market trial for Gore Septal Occluder in PFO closure (REDUCE trial)*
    • Primary Investigator: Brent Gordon, MD 

*Currently recruiting participants. 

Heart Failure & Transplant Research 

Our heart failure and transplant team is involved in some of the most exciting clinical research trials in the field. Currently, that includes the following. 

Clinical Trials

  • Multicenter, open-label, single dose study to evaluate safety, tolerability and pharmacokinetics of LCZ696 followed by a 52-week randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared with enalapril in pediatric patients from 1 month to < 18 years of age with heart failure due to systemic left ventricle systolic dysfunction.
    • Also known as: PANORAMA-HF*
    • Sponsor: Novartis Pharmaceuticals Corporation 
    • Primary Investigator: Matthew Bock, MD
  • Phase III Multi-Center Open-Label Randomized Trial Comparing Everolimus and Low-Dose Tacrolimus to Tacrolimus and Mycophenolate Mofetil (TAC/MMF) initiated at 6 Months Post Heart Transplant to Prevent Long-term Complications after Pediatric Heart Transplantation
    • Also known as: TEAMMATE TRIAL*
    • Sponsor: U.S. Department of Defense
    • Primary Investigator: Matthew Bock, MD
  • Integrating Multi-parametric Echocardiography with Computer Assisted Analyses in Detection for Early Allograft Rejection in Pediatric Heart Transplant Recipients: A Pilot Prospective Multicenter Trial 
    • Also known as: ECHO-E
    • Sponsor: Enduring Hearts
    • Primary Investigator: Matthew Bock, MD 
*Currently recruiting participants.